Table 1 Baseline demographic and clinical characteristics
Variables | Patients with tissue samples no. (%) | Patients without tissue samples no. (%) |
|---|---|---|
Gender | Â | Â |
 Male | 14 (78%) | 5 (71%) |
 Female | 4 (22%) | 2 (29%) |
Age (years) | Â | Â |
 ≥ 60 | 2 (12%) | 4 (57%) |
 < 60 | 16 (88%) | 3 (43%) |
KPS score | Â | Â |
 ≥ 90 | 11 (61%) | 3 (43%) |
 70-90 | 7 (39%) | 4 (57%) |
MSKCC risk factors | Â | Â |
 0 (favorable) | 8 (44%) | 3 (43%) |
 1-2 (intermediate) | 8 (44%) | 1 (14%) |
 ≥ 3 (poor) | 2 (12%) | 3 (43%) |
No. of metastatic sites | Â | Â |
 1 | 8 (44%) | 2 (29%) |
 2 | 7 (39%) | 5 (71%) |
 ≥ 3 | 3 (17%) | 0 (0%) |
Prior therapy* | Â | Â |
 First-line | 18 (100%) | 7 (100%) |
 Second-line | 8 (44%) | 2 (29%) |
 Third-line | 1 (6%) | 1 (14%) |
Regimens of prior therapy* | Â | Â |
 Sunitnib | 7 (39%) | 1 (14%) |
 Sorafenib | 10 (56%) | 5 (71%) |
 Axitinib | 4 (22%) | 1 (14%) |
 Pazopanib | 0 (0%) | 1 (14%) |
 Cytokines | 3 (17%) | 2 (29%) |
 Chemotherapy | 4 (4%) | 0 (0%) |